替吉奥单药或联合铂类治疗晚期非小细胞肺癌患者疗效与安全性的Meta评价

The efficacy and safety of S-1 monotherapy or combined with platinum chemotherapy in the treatment of patients with advanced NSCLC:a meta-analysis

目的用Meta分析评价替吉奥单药或联合铂类系统化疗方案在治疗晚期非小细胞肺癌(NSCLC)患者的疗效与安全性。方法计算机检索CNKI、PubMed、Web of Science和Cochrane Library等数据库,纳入以替吉奥单药或联合铂类方案系统化疗为观察组,紫杉醇、多西他赛及吉西他滨单药或联合铂类化疗方案为对照组的随机临床对照试验,采用Cochrane系统评价方法进行文献质量评价,RevMan 5.3.5软件进行数据统计分析。结果纳入25项研究,共3977例患者。有效性方面,观察组治疗晚期NSCLC患者的有效率和疾病控制率与对照组相似,结果无统计学意义[有效率:OR=0.97,95%CI(0.83,1.13),P=0.66;疾病控制率:OR=1.11,95%CI(0.92,1.32)P=0.27]。在安全性上,即降低多种化疗药物不良反应发生率方面,观察组与对照组相比具有显著优势(P<0.05)。结论晚期NSCLC患者选择系统化疗方案时,可推荐使用替吉奥单药或联合铂类化疗方案。

Objective To investigate the efficacy and safety of S-1 monotherapy or combined with platinum chemotherapy in the treatment of patients with advanced NSCLC.Methods Systematic searches were performed for randomized controlled trials with the CNKI,PubMed,Web of Science and Cochrane Library.S-1 monotherapy or combined with platinum chemotherapy was the observation group.Paclitaxel,docetaxel and gemcitabine monotherapy or combined with platinum chemotherapy were the control group.The Cochrane systematic review method was used for literature quality evaluation and RevMan 5.3.5 software was used for statistical analysis.Results 3977 patients were enrolled in 25 studies.The effective rate and disease control rate in the observation group were similar to those in the control group with no statistical significance[ORR:OR=0.97,95%CI(0.83,1.13),P=0.66;DCR:OR=1.11,95%CI(0.92,1.32)P=0.27].In terms of safety,there were less adverse drug reactions in the observation group compared to the control group with statistical significance(P<0.05).Conclusion S-1 monotherapy or combined with platinum chemotherapy is recommended for patients with advanced NSCLC.